Is Inositol Insomnia Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Inositol Insomnia Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Major Depressive Disorder (MDD) diagnoses have drastically increased in the United States from 6.5% to 21-30% since 2019, burdening individuals and society alike. [White AJ (2026); evidence level 1] - We found that subjects with MDD had significantly decreased N-acetylaspartate (NAA; Hedges' g = -0.16, 95% CI -0.299 to -0.030, p = 0.017), and gamma-aminobutyric acid (GABA; Hedges' g = -0.26, 95% CI -0.434 to -0.082, p = 0.004), and increased levels of glutamine (Gln; Hedges' g = 0.21, 95% CI 0.105 to 0.311, p < 0.001) in the ACC. [White AJ (2026); evidence level 1] - Subgroup analyses suggested significantly increased NAA detected by magnets stronger than 1.5 Tesla only, glutamate (Glu) in the dorsal ACC only and significantly increased myo-inositol (mI) and choline (Cho) in exclusively unmedicated subjects. [White AJ (2026); evidence level 1] - Despite considerable efforts to understand the pathogenesis of MDD, the heterogeneity of the disorder has made it difficult to delineate its underpinnings, highlighting the need for biomarker identification. [White AJ (2026); evidence level 1] - Evidence review A systematic literature review and meta-analysis were conducted using PubMed/MEDLINE, Embase, and Web of Science (2015-2024), following PRISMA guidelines. [Du J (2026); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.